Abstract
Aspirin has long been the mainstay of primary and secondary prevention against myocardial infarction and ischemic cerebrovascular events. However, the incremental value of aspirin for primary prevention has recently been subject to debate given data from recent large clinical trials, as the net clinical benefit is small. In secondary prevention, aspirin is still strongly recommended.
Efforts in obtaining more efficient antiplatelet agents and to reduce cardiovascular morbidity and mortality have led to the development of new adenosine diphosphate (ADP) receptor antagonists, which are superior to clopidogrel. New generation antiplatelet drugs i.e. prasugrel and ticagrelor aim to reduce atherothrombotic events, mortality and stent thrombosis, as well as overcome low- or non-response to clopidogrel. Further agents with antiplatelet properties are being investigated at present.
This overview aims to give insights into the rapidly changing field of antiplatelet strategies in cardiovascular diseases.
Keywords: Atherothrombosis, cardiovascular disease, primary prevention, secondary prevention, novel antithrombotics, acetyl salicylic acid, adenosine diphosphate (ADP), infarction, ischemic cerebrovascular, clopidogrel
Current Pharmaceutical Design
Title: Antiplatelet Therapy in Atherothrombotic Cardiovascular Diseases for Primary and Secondary Prevention: A Focus on Old and New Antiplatelet Agents
Volume: 18 Issue: 6
Author(s): Burak Pamukcu, Kurt Huber and Gregory Y.H. Lip
Affiliation:
Keywords: Atherothrombosis, cardiovascular disease, primary prevention, secondary prevention, novel antithrombotics, acetyl salicylic acid, adenosine diphosphate (ADP), infarction, ischemic cerebrovascular, clopidogrel
Abstract: Aspirin has long been the mainstay of primary and secondary prevention against myocardial infarction and ischemic cerebrovascular events. However, the incremental value of aspirin for primary prevention has recently been subject to debate given data from recent large clinical trials, as the net clinical benefit is small. In secondary prevention, aspirin is still strongly recommended.
Efforts in obtaining more efficient antiplatelet agents and to reduce cardiovascular morbidity and mortality have led to the development of new adenosine diphosphate (ADP) receptor antagonists, which are superior to clopidogrel. New generation antiplatelet drugs i.e. prasugrel and ticagrelor aim to reduce atherothrombotic events, mortality and stent thrombosis, as well as overcome low- or non-response to clopidogrel. Further agents with antiplatelet properties are being investigated at present.
This overview aims to give insights into the rapidly changing field of antiplatelet strategies in cardiovascular diseases.
Export Options
About this article
Cite this article as:
Pamukcu Burak, Huber Kurt and Y.H. Lip Gregory, Antiplatelet Therapy in Atherothrombotic Cardiovascular Diseases for Primary and Secondary Prevention: A Focus on Old and New Antiplatelet Agents, Current Pharmaceutical Design 2012; 18 (6) . https://dx.doi.org/10.2174/138161212799277716
DOI https://dx.doi.org/10.2174/138161212799277716 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Radionuclide Imaging in Patients with Ischemic Heart Failure
Current Medical Imaging Anti-TNF Treatment in Rheumatoid Arthritis
Current Pharmaceutical Design Obstructive Sleep Apnea and Cardiovascular Disease - A New Target for Treatment
Current Pharmaceutical Design CXCR4-CXCL12-Dependent Inflammatory Network and Endothelial Progenitors
Current Medicinal Chemistry Are the Myokines the Mediators of Physical Activity-Induced Health Benefits?
Current Pharmaceutical Design The Effects of Vitamin B in Depression
Current Medicinal Chemistry Synthesis and Antioxidant Activity of 1,2,4-Triazole linked Thieno[2,3- d]pyrimidine Derivatives
Letters in Drug Design & Discovery Copper as a Biocidal Tool
Current Medicinal Chemistry Pathophysiology of Coronary Thrombus Formation and Adverse Consequences of Thrombus During PCI
Current Cardiology Reviews Silicon in Plant Tolerance Against Environmental Stressors: Towards Crop Improvement Using Omics Approaches
Current Proteomics Natural Phenolic Compounds as Cardiovascular Therapeutics: Potential Role of their Antiinflammatory Effects
Current Vascular Pharmacology Statistically Designed Extraction of Herbs Using Ultrasound Waves: A Review
Current Pharmaceutical Design Simulating the Interactions of Toxins with K+ Channels
Current Pharmaceutical Design Disturbance of Inorganic Phosphate Metabolism in Diabetes Mellitus: Its Impact on the Development of Diabetic Late Complications
Current Diabetes Reviews Anti-Angiogenic Effects of Resveratrol on Cerebral Angiogenesis
Current Neurovascular Research The Antidiabetic PPARγ Ligands: An Update on Compounds in Development
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Nicotinic Receptors Containing the α7 Subunit: A Model for Rational Drug Design
Current Medicinal Chemistry Involvement of the Toxic AGEs (TAGE)-RAGE System in the Pathogenesis of Diabetic Vascular Complications: A Novel Therapeutic Strategy
Current Drug Targets Perinatal Heart Programming: Long-term Consequences
Current Medicinal Chemistry Micronutrient Biofortification in Rice through New Breeding Techniques (NBTs): Bangladesh Perspective
Current Nutraceuticals